EarningsBioNTech recorded a net loss per diluted share of €3.36 per share—meaningfully worse than the previous forecast for net earnings of €1.16 per share.
Product PerformanceBioNTech and Pfizer's combo influenza-COVID-19 vaccine only met one of the two primary immunogenicity objectives in a Phase 3 trial.
Regulatory IssuesBNT326, the company’s HER3 antibody drug conjugate (ADC), was placed under a partial clinical hold by the FDA resulting in an enrollment pause of US patients.